Every vial in the Bastet Biosciences catalog carries a designation that appears on the label, in every listing, and on every Certificate of Analysis: Research Use Only, or RUO. This is not a legal disclaimer buried in fine print. It is the defining framework under which these compounds are manufactured, supplied, and studied.

The Scientific Context

Research peptides exist at a stage of scientific investigation that precedes clinical approval. The therapeutic landscape is populated by compounds in three broad categories: those that have received regulatory approval for human use, those that are in active clinical trials, and those that remain in preclinical or early investigational stages.

Most compounds in the Bastet catalog, and most peptides in the broader research ecosystem, belong to the third category. The preclinical data supporting their study is substantial. The human clinical data required for therapeutic approval, in most cases, is not.

What RUO Allows

A Research Use Only designation indicates that the compound is supplied for:

• In vitro laboratory research
• Cell culture studies
• Preclinical animal model research conducted under appropriate institutional oversight
• Analytical method development and validation
• Reference standard use in comparative research

What RUO Does Not Allow

An RUO designation explicitly excludes:

• Diagnostic use in humans
• Therapeutic administration to humans
• Clinical decision-making based on the compound’s activity
• Veterinary clinical use outside of sanctioned research protocols

Research Use Only is not a workaround for clinical access. It is a framework that protects the integrity of preclinical science and the safety of anyone who might otherwise be exposed to an unapproved compound.

The Role of Institutional Oversight

In legitimate research contexts, the use of investigational compounds is governed by Institutional Review Boards (IRBs), Institutional Animal Care and Use Committees (IACUCs), and other oversight bodies that exist precisely because the science is still being written.

When a peptide moves from RUO status to clinical investigation, it does so under the supervision of these bodies, with protocols, informed consent, and safety monitoring that RUO by definition does not provide.

Why This Framework Exists

The reason for the distinction between research and therapeutic compounds is not bureaucratic. It is historical. Every therapeutic agent that has caused harm at population scale has a paper trail that begins with compounds moving too quickly from laboratory promise to unsupervised use.

The RUO framework exists to preserve the space in which promising science can be carefully evaluated, replicated, challenged, and, when warranted, advanced through formal clinical channels. Bastet Biosciences supplies its compounds within that framework, and expects its customers to operate within it as well.

Further reading

[1] U.S. Food and Drug Administration. Research Use Only (RUO) and Investigational Use Only (IUO) Products. FDA Guidance Document, 2013.

[2] 21 CFR Part 50 – Protection of Human Subjects (Institutional Review Boards).

[3] U.S. Department of Health and Human Services. Office for Human Research Protections (OHRP).